Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017
Data Examining RBX2660 Treatment in Relation to “Healthy” Gut Microbiome, Placebo Response Rates in a Meta Analysis and Microbiome Engraftment to be Showcased
Download this press release (158 KB).
ROSEVILLE, MN (June 01, 2017) — Rebiotix Inc., a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it will present three posters during the American Society for Microbiology’s ASM Microbe 2017, being held June 1-5, 2017 in New Orleans. One poster will be part of the general poster sessions, and two will be highlighted as “Poster Talks,” where they will be presented orally with an opportunity to take questions from the audience. The posters include data analyses from clinical studies featuring RBX2660, Rebiotix’s Phase 3-ready broad spectrum microbiota suspension designed to rehabilitate the human microbiome by delivering live microbes into a patient’s intestinal tract to treat disease.
The schedule of Rebiotix-focused presentations at ASM Microbe 2017 is as follows: